Pyoderma Gangrenosum AND Neutrophilic Dermatoses — Written Clinical Reasoning · Phys Written Answers

Prompt

DCE-style written reasoning for Pyoderma Gangrenosum AND Neutrophilic Dermatoses.

SAQ 1 — Integrated plan (12 marks)

Prompt: Provide a prioritised problem list and management sequence for this presentation. [1] [2]

1. Frame and red flags (3 marks) [1]

State the working diagnosis/syndrome, acuity, and what would force emergency treatment now. [1] [2]

2. Discriminating assessment (3 marks) [2]

List the key history, examination and investigations that separate dangerous differentials from benign mimics. [1] [2]

3. Treatment sequence (4 marks) [1] [3]

Immediate stabilisation, disease-specific therapy, monitoring, and complications prevention. [1] [2] [3]

4. Follow-up and communication (2 marks) [2]

Disposition, safety-net advice, and who owns follow-up. [1] [2]

Prompt: Name two high-yield traps in Pyoderma Gangrenosum AND Neutrophilic Dermatoses and how you avoid them. [1] [2]

Trap one: delayed escalation of a high-risk feature — avoid by explicit red-flag checklist. [1]

Trap two: therapy mismatched to mechanism — avoid by confirming the discriminating test before escalating treatment. [2] [3]

[1]Balan K, Elston DM IL-1-targeted therapy in dermatologic conditions J Am Acad Dermatol, 2026.PMID 42264383
[2]Kerniss H, Olbrich H, Curman P, Ständer S, et al. Pyoderma gangrenosum is associated with excess incident major atherothrombotic events Atherosclerosis, 2026.PMID 42263577
[3]Rahman S, Akuffo-Addo E, Geng R, Bestavros S, et al. Genital Pyoderma Gangrenosum: A Systematic Review of Reported Cases and Treatment Outcomes J Cutan Med Surg, 2026.PMID 42109214
[4]Haddadin OM, Jacobson ME, Becker SL, Chen D, et al. Minimum dataset for treatment effectiveness in pyoderma gangrenosum for an international registry: an international multidisciplinary eDelphi consensus Br J Dermatol, 2026.PMID 41784109
[5]Yamamoto T, Yamasaki K, Yamanaka K, Komine M, et al. Clinical guidance of pyoderma gangrenosum 2022 J Dermatol, 2023.PMID 37311717
[6]Maverakis E, Ma C, Shinkai K, Fiorentino D, et al. Diagnostic Criteria of Ulcerative Pyoderma Gangrenosum: A Delphi Consensus of International Experts JAMA Dermatol, 2018.PMID 29450466
[7]Xi Y, Yao T, Zhang C, Zhuang T Effectiveness of safety care and clinical nursing pathway in patients undergoing cardiovascular intervention: a randomized controlled trial Perioper Med (Lond), 2026.PMID 42469924
[8]Marks FJ, Walters SJ, Sutton L, Jacques RM What statistical methods are more appropriate for predicting recruitment at the design stage of a randomised controlled trial? Trials, 2026.PMID 42469922